Glaxo beats expectations with boost from Covid treatment

Sales of coronavirus drug Xevudy reached £1.3 billion over the first quarter of this year.

August Graham
Wednesday 27 April 2022 09:12
Sales of Glaxo’s shingles vaccine also boomed in the first quarter of the year (Andy Buchanan/PA)
Sales of Glaxo’s shingles vaccine also boomed in the first quarter of the year (Andy Buchanan/PA)

A strong performance from its Covid antibody treatment helped drugs giant GlaxoSmithKline blast through expectations over the last three months.

The business turned over £9.8 billion in the first quarter, up 32% from the same period last year.

It was considerably ahead of the £9.2 billion experts had been expecting, and benefitted from good performances from the Covid drug and a shingles vaccine.

Sales of Xevudy, the Covid treatment, reached more than £1.3 billion over the quarter. Most of that came from the US, where the medicine reached a turnover of £770 million.

The medicine is given through a drip in hospital. It works by injecting a patient with artificial antibodies which stick to the virus.

Meanwhile sales of shingles vaccine Shingrix had dropped significantly during the pandemic a year ago when priority was given to dishing out Covid jabs.

We have delivered strong first quarter results in this landmark year for GSK, as we separate consumer healthcare and start a new period of sustained growth

Emma Walmsley, chief executive

Sales of Shingrix therefore bounced back in the first quarter of this year, more than doubling to £698 million.

Chief executive Emma Walmsley said: “Our results reflect further good momentum across specialty medicines and vaccines, including the return to strong sales growth for Shingrix and continuing pipeline progress.”

The business said it is on track to split from its consumer healthcare arm in July. The multibillion-pound company will be renamed Haleon.

“We have delivered strong first quarter results in this landmark year for GSK, as we separate consumer healthcare and start a new period of sustained growth,” Ms Walmsley said.

“We also continue to see very good momentum in consumer healthcare, demonstrating strong potential of this business ahead of its proposed demerger in July, to become Haleon.”

GSK reconfirmed its guidance for the rest of the year, saying it expects to grow sales by between 5% and 7%. Meanwhile adjusted operating profit is expected to grow between 12% and 14%.

The guidance “excludes any contribution from Covid-19 solutions”, GSK said.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in